Table 7 Demographic and clinical characteristics of patients with Intrahepatic cholangiocarcinoma without surgery in the CSS group. IQR interquartile range.
Characteristic | Overall | Training cohort | Validation cohort | P value |
|---|---|---|---|---|
Total patients, n | 722 | 505 | 217 | |
Age, n (%) | 0.332 | |||
< 50 | 76 (10.5%) | 59 (11.1%) | 17 (7.8%) | |
50–64 | 272 (37.7%) | 182 (37.0%) | 90 (41.5%) | |
65–79 | 308 (42.7%) | 217 (42.6%) | 91 (41.9%) | |
≥ 80 | 66 (9.1%) | 47 (9.3%) | 19 (8.8%) | |
Sex, n (%) | 0.695 | |||
Male | 384 (53.2%) | 271 (53.7%) | 113 (52.1%) | |
Female | 338 (46.8%) | 234 (46.3%) | 104 (47.9%) | |
Race, n (%) | 0.278 | |||
White | 574 (79.5%) | 394 (78.0%) | 180 (82.9%) | |
Black | 62 (8.6%) | 45 (8.9%) | 17 (7.8%) | |
Other | 86 (11.9%) | 66 (13.1%) | 20 (9.2%) | |
AJCC T stage, n (%) | 0.524 | |||
T1 | 183 (25.3%) | 132 (26.1%) | 51 (23.5%) | |
T2 | 379 (52.5%) | 260 (51.5%) | 119 (54.8%) | |
T3 | 113 (15.7%) | 83 (16.4%) | 30 (13.8%) | |
T4 | 47 (6.5%) | 30 (5.9%) | 17 (7.8%) | |
AJCC N stage, n (%) | 0.953 | |||
N0 | 438 (60.7%) | 306 (60.6%) | 132 (60.8%) | |
N1 | 284 (39.3%) | 199 (39.4%) | 85 (39.2%) | |
AJCC M stage, n (%) | ||||
M0 | 422 (58.4%) | 290 (57.4%) | 132 (60.8%) | 0.395 |
M1 | 300 (41.6%) | 215 (42.6%) | 85 (39.2%) | |
Grade, n (%) | 0.421 | |||
I | 69 (9.6%) | 53 (10.5%) | 16 (7.4%) | |
II | 293 (40.6%) | 202 (40.0%) | 91 (41.9%) | |
III + IV | 360 (49.9%) | 250 (49.5%) | 110 (50.7%) | |
Tumor size, n (%) | 0.012 | |||
≤ 5 cm | 170 (23.5%) | 132 (26.1%) | 38 (17.5%) | |
> 5 cm | 552 (76.5%) | 373 (73.9%) | 179 (82.5%) | |
Chemotherapy, n (%) | 0.270 | |||
No | 222 (30.7%) | 149 (29.5%) | 73 (33.6%) | |
Yes | 500 (69.3%) | 356 (70.5%) | 144 (66.4%) | |
Radiotherapy, n (%) | 0.661 | |||
No | 599 (83.0%) | 421 (83.4%) | 178 (82.0%) | |
Yes | 123 (17.0%) | 84 (16.6%) | 39 (18.0%) | |
Survival, median (IQR) | 9 (3.0, 18.00) | 9 (4.0, 17.50) | 9 (3.0, 18.00) | 0.687 |
